111 related articles for article (PubMed ID: 2215766)
1. [Pharmaco-morbidity linking: a potential instrument for post-marketing surveillance].
Stricker BH; Herings RM; Bakker A; Valkenburg HA; Sturmans F
Ned Tijdschr Geneeskd; 1990 Sep; 134(39):1886-9. PubMed ID: 2215766
[No Abstract] [Full Text] [Related]
2. [Physician and pharmaceutical industry. II. Postmarketing surveillance].
Offerhaus L
Ned Tijdschr Geneeskd; 1992 Jan; 136(1):36-41. PubMed ID: 1728761
[No Abstract] [Full Text] [Related]
3. [Necessity and difficulties of quantitative drug monitoring].
Lagier G; Dally S; Vincens M; Castot A
Therapie; 1983; 38(3):319-23. PubMed ID: 6612668
[No Abstract] [Full Text] [Related]
4. Round table: Post-marketing evaluation of fertility-regulating drugs as viewed by the pharmaceutical industry.
Hum Reprod; 1987 Apr; 2(3):241-63. PubMed ID: 3597744
[No Abstract] [Full Text] [Related]
5. Current French system of post-marketing drug surveillance.
Albengres E; Gauthier F; Tillement JP
Int J Clin Pharmacol Ther Toxicol; 1990 Jul; 28(7):312-4. PubMed ID: 2387656
[TBL] [Abstract][Full Text] [Related]
6. Post marketing surveillance of new drugs. Patient safety in the hands of GPs.
Marley JE
Aust Fam Physician; 1989 Sep; 18(9):1133-5. PubMed ID: 2590077
[TBL] [Abstract][Full Text] [Related]
7. Misclassification in epidemiologic studies of adverse drug reactions using large managerial data bases.
Graham DJ; Smith CR
Am J Prev Med; 1988; 4(2 Suppl):15-24. PubMed ID: 3079350
[No Abstract] [Full Text] [Related]
8. [Post-marketing surveillance of drugs: epidemiologic approach].
Stanulović M; Jakovljević V; Sabo A
Med Pregl; 1987; 40(11-12):573-7. PubMed ID: 3331415
[No Abstract] [Full Text] [Related]
9. [PSUR - Instrument for pharmacovigilance and patient safety. What pharmacists should know about periodic safety update reports].
Strehl E
Med Monatsschr Pharm; 2009 Sep; 32(9):347-9. PubMed ID: 19795697
[No Abstract] [Full Text] [Related]
10. Revised ADR report permits internal review of drug experience.
Jeffrey LP
Pharm Times; 1986 Dec; 52(12):48-50. PubMed ID: 10317827
[No Abstract] [Full Text] [Related]
11. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
12. Statewide test of a new postmarketing drug surveillance system.
Fisher S; Bryant SG; Solovitz BL; Kluge RM
Tex Med; 1987 Aug; 83(8):59-62. PubMed ID: 3660262
[No Abstract] [Full Text] [Related]
13. Post marketing surveillance. Traps for the unwary.
Marley J; Mant A
Aust Fam Physician; 1993 Jun; 22(6):1009-11, 1013. PubMed ID: 8338446
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical postmarket review: fact or fiction?
Schanz SJ
Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391
[No Abstract] [Full Text] [Related]
15. Critical reflection on the collection and evaluation of adverse drug reaction data.
Venulet J
Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S48-53. PubMed ID: 3842691
[No Abstract] [Full Text] [Related]
16. Epidemiologic assessment of adverse drug effects.
Stern RS
Semin Dermatol; 1989 Sep; 8(3):136-40. PubMed ID: 2701270
[No Abstract] [Full Text] [Related]
17. [Is imputation in drug surveillance reliable?].
Girard M
Therapie; 1984; 39(3):291-6. PubMed ID: 6463954
[No Abstract] [Full Text] [Related]
18. Potential role of postmarketing research.
Venulet J
Drugs Exp Clin Res; 1987; 13(11):673-83. PubMed ID: 3443043
[TBL] [Abstract][Full Text] [Related]
19. [Detection of drug side effects at the Heidelberg Medical Clinic].
Jacubeit T; Drisch D
Verh Dtsch Ges Inn Med; 1989; 95():690-3. PubMed ID: 2603505
[No Abstract] [Full Text] [Related]
20. [30 years' spontaneous recording systems of German physicians--results and experiences].
Kimbel KH
Verh Dtsch Ges Inn Med; 1989; 95():683-6. PubMed ID: 2603503
[No Abstract] [Full Text] [Related]
[Next] [New Search]
